John M. Baratta

John M. Baratta

Auto-generated profile, based on publicly available information

John M. Baratta

Department of Physical Medicine and Rehabilitation UNC‐Chapel Hill Chapel Hill North Carolina USA

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 August 2021 in PM&R
Verified
Journal Article
Open access
PDF file
JHJoseph E. Herrera
Joseph E. Herrera
WNWilliam N. Niehaus
William N. Niehaus
JWJonathan Whiteson
Jonathan Whiteson
AAAlba Azola
Alba Azola
JBJohn M. Baratta
John M. Baratta
BABenjamin Abramoff
Benjamin Abramoff
Click on the article title to read more.

22 April 2025 in PM&R
Verified
Journal Article
Closed access
ACAbby L Cheng
Abby L Cheng
EHEric Herman
Eric Herman
BABenjamin Abramoff
Benjamin Abramoff
JAJordan R. Anderson
Jordan R. Anderson
AAAlba Azola
Alba Azola
WNWilliam N. Niehaus
William N. Niehaus

22 January 2024 in medRxiv
Verified
Preprint
Open access
PDF file
APAlexander Preiss
Alexander Preiss
Abhishek BhatiaAbhishek Bhatia
Abhishek Bhatia
LALeyna V. Aragon
Leyna V. Aragon
JBJohn M. Baratta
John M. Baratta
MBMonika Baskaran
Monika Baskaran
TCThe Recover Ehr Cohort
The Recover Ehr Cohort
Background: Preventing and treating post-acute sequelae of SARS-CoV-2 infection (PASC), commonly known as Long COVID, has become a public health priority. Researchers have begun to explore whether Paxlovid treatment in the acute phase of COVID-19 could help prevent the onset of PASC. Methods and Findings: We used electronic health records from the National Clinical Cohort Collaborative (N3C) to define a cohort of 410,026 patients who had COVID-19 since April 1, 2022, and were eligible for Paxlovid treatment due to risk for progression to severe COVID-19. We used the target trial emulation framework to estimate the effect of Paxlovid treatment on PASC incidence. The treatment group was defined as outpatients prescribed Paxlovid within five days of COVID-19 index, and the control group was defined as all patients meeting eligibility criteria not in the treatment group. The follow-up period was 180 days. We estimated overall PASC incidence using a computable phenotype. We also measured incident cognitive, fatigue, and respiratory symptoms in the post-acute period. Paxlovid treatment had a small effect on overall PASC incidence (relative risk [RR] 0.94; 95% CI [0.90, 0.99]; p=0.011). It had a slightly stronger protective effect against cognitive (RR 0.86; 95% CI [0.77, 0.95]; p<0.001) and fatigue (RR 0.92; 95% CI [0.86, 0.97]; p=0.002) symptoms. Conclusions: In this study, Paxlovid had a weaker preventative effect on PASC than in prior observational studies, suggesting that Paxlovid is unlikely to become a definitive solution for preventing PASC. Differing effects by symptom cluster suggest that the etiology of cognitive and fatigue symptoms may be more closely related to viral load than that of respiratory symptoms. Future research should explore potential heterogeneous treatment effects across PASC subphenotypes. AUTHOR SUMMARY: Why was this study done?: Paxlovid is indicated to prevent severe COVID-19. Long COVID is more likely after more severe COVID-19, so there is a plausible mechanism for Paxlovid to reduce the risk of developing Long COVID by preventing severe COVID-19. Only a few studies have examined the relationship between Paxlovid and Long COVID, with mixed results. To our knowledge, no studies have used causal inference methods to estimate Paxlovid’s effect on PASC. If Paxlovid helps prevent Long COVID, it could be a powerful addition to the public health effort to reduce the burden of COVID-19. What did the researchers do and find?: We used a cohort of 410,026 patients from the National Covid Cohort Collaborative’s (N3C’s) electronic health record database to estimate the effect of Paxlovid treatment during acute COVID-19 on the likelihood of developing Long COVID. We used the target trial emulation technique to estimate the causal effect of Paxlovid treatment using observational data. We found that Paxlovid treatment had a small effect on overall Long COVID incidence. We found that Paxlovid treatment had a slightly stronger effect on certain symptoms (cognitive and fatigue) of Long COVID. What do these findings mean?: Paxlovid is unlikely to become a definitive solution for preventing Long COVID. However, Paxlovid may have a stronger effect on certain subtypes of Long COVID. This difference in effect by symptom also suggests that viral load may be a more common cause of cognitive and fatigue symptoms than of other Long COVID symptoms. This study’s main limitation is that it estimates causal effects, but it is not randomized like a clinical trial. Instead, we control for other variables which could bias the estimate, but if we missed some important variables, the estimates could be incorrect.

14 May 2023 in Global Advances in Integrative Medicine and Health
Verified
Journal Article
Open access
JBJessica L Barnhill
Jessica L Barnhill
IRIsabel J Roth
Isabel J Roth
VMVanessa E Miller
Vanessa E Miller
JBJohn M Baratta
John M Baratta
ACAisha Chilcoat
Aisha Chilcoat
PGPaula Gardiner
Paula Gardiner
Background: Long COVID is a common, debilitating post-infectious illness for which effective management is unknown. Integrative Medical Group Visits (IMGV) are effective interventions for chronic conditions and could benefit Long COVID patients. More information is needed regarding existing patient reported outcome measures (PROMs) to evaluate efficacy of IMGV for Long COVID. Objective: This study assessed the feasibility of specific PROMS to evaluate IMGVs for Long COVID. Findings will inform future efficacy trials. Methods: The Perceived Stress Scale (PSS-10), General Anxiety Disorder two-question tool (GAD-2), Fibromyalgia Symptom Severity scale (SSS), and Measure Yourself Medical Outcome Profile (MYMOP®) were collected pre- and post-group by teleconferencing platform or telephone and compared using paired t-tests. Patients were recruited from a Long COVID specialty clinic where they participated in 2-hour - 8 weekly IMGV sessions online. Results: Twenty-seven participants enrolled and completed pre-group surveys. Fourteen participants were reachable by phone post-group and completed all pre and post PROMs (78.6% female, 71.4% non-Hispanic White, mean age 49). MYMOP® primary symptomatology was fatigue, shortness of breath and “brain fog”. Symptoms decreased in interference when compared to pre-group levels (mean difference −1.3 [95% CI-2.2, −.5]). PSS scores decreased (−3.4 [95% CI -5.8, −1.1]), and GAD-2 mean difference was −1.43 (95% CI –3.12, .26). There were no changes in SSS scores of fatigue (−.21 [95% CI -.68,0.25]), waking unrefreshed (.00 [95%CI -.32, −.32]), or trouble thinking (−.21 [95% CI -.78,0.35]). Conclusion: All PROMs were feasible to administer via teleconferencing platform or telephone. The PSS, GAD-2 and MYMOP® are promising PROMs to track Long COVID symptomatology among IMGV participants. The SSS, while feasible to administer, did not change compared to baseline. Larger, controlled studies are needed to determine the efficacy of virtual IMGVs to address the needs of this large and growing population.

15 September 2025 in PLOS Medicine
Verified
Journal Article
Open access
PDF file
APAlexander Preiss
Alexander Preiss
Abhishek BhatiaAbhishek Bhatia
Abhishek Bhatia
LALeyna V. Aragon
Leyna V. Aragon
JBJohn M. Baratta
John M. Baratta
MBMonika Baskaran
Monika Baskaran
EPEmily Pfaff
Emily Pfaff
Background: Preventing and treating post-acute sequelae of COVID-19 infection (PASC), commonly known as Long COVID, has become a public health priority. This study tests whether Paxlovid treatment in the acute phase of COVID-19 could help prevent the onset of PASC. Methods and findings: We used electronic health records from the National Clinical Cohort Collaborative to define a cohort of 445,738 patients who had COVID-19 since April 1, 2022, and were eligible for Paxlovid treatment due to risk for progression to severe COVID-19. We used the target trial emulation framework to estimate the effect of Paxlovid treatment on PASC incidence. We emulated a series of six sequential trials: one for each day of a 5-day treatment grace period. For each sequential trial, the treatment group was defined as patients prescribed Paxlovid on the trial start day, and the control group was defined as all patients meeting eligibility criteria who remained untreated on the trial start day. We pooled individual record-level data from the sequential trials for analysis. The follow-up period was 180 days. The primary outcome was overall PASC incidence measured using a computable phenotype. Secondary outcomes were incident cognitive, fatigue, and respiratory symptoms in the post-acute period. We controlled for a wide range of demographic and medical history covariates. Compared to the control group, Paxlovid treatment did not have a significant effect on overall PASC incidence or incident respiratory symptoms. It had a small protective effect against cognitive (relative risk [RR] 0.91; 95% CI [0.84, 0.98]; p = 0.019) and fatigue (RR 0.94; 95% CI [0.90, 0.98]; p = 0.002) symptoms. Finally, we estimated Paxlovid’s effect on overall PASC incidence across strata of age, COVID-19 vaccination status, and Charlson Comorbidity Index (CCI) prior to COVID-19. We found small protective effects among patients aged 65 years or more (RR 0.92; 95% CI [0.88, 0.97]; p < 0.001; absolute risk difference [ARD] −0.43%; number needed to treat [NNT] 233) and with a CCI of 3 or 4 (RR 0.83; 95% CI [0.75, 0.92]; p < 0.001; ARD −1.30%; NNT 76). This study’s main limitation is that the causal interpretation relies on the assumption that we controlled for all confounding variables. Conclusions: Although some prior observational studies suggested that Paxlovid held promise as a PASC preventive, this study—with a large, nationally sampled cohort; a contemporary study period; and causal inference methodology—found that Paxlovid treatment during acute COVID-19 had no effect on subsequent PASC incidence. Stratified analyses suggest that Paxlovid may have a small protective effect among higher-risk patients, but the NNT is high. In conclusion, we see Paxlovid as unlikely to become a definitive solution for PASC prevention.

3 November 2021 in PM&R
Verified
Journal Article
Open access
PDF file
JHJoseph E. Herrera
Joseph E. Herrera
WNWilliam N. Niehaus
William N. Niehaus
JWJonathan Whiteson
Jonathan Whiteson
AAAlba Azola
Alba Azola
JBJohn M. Baratta
John M. Baratta
BABenjamin Abramoff
Benjamin Abramoff
Click on the article title to read more.